Controlled correspondence: FDA offers advice for generic sponsors
Regulatory NewsJoanne S. Eglovitch
GDUFAGenericsHealth Authority meeting and communication strategyProduct developmentRegulatory Intelligence/PolicyRegulatory strategyResearch, Design and DevelopmentSubmission and registrationUnited StatesUS Food and Drug Administration (FDA)User fees